

2 0 2 4



REVIEW OF ACTIVITIES AND ACHIEVEMENTS



PERSATUAN PESAKIT
IMUNODEFISIENSI PRIMER
MALAYSIA (MYPOPI)

WWW.MYPOPI.ORG



CONTACT INFORMATION

PERSATUAN PESAKIT IMUNODEFISIENSI PRIMER MALAYSIA

ROS Reg. No:
PPM-008-14-15082014

35G, Jalan Kemuning
Prima C33/C, 40400 Shah
Alam, Selangor D.E.,
Malaysia.

[HTTPS://WWW.MYPOPI.ORG/](https://www.mypopi.org/)

TABLE OF CONTENT



01 A Message from President MYPOPI

02 Our Executive Committees and Board Members

03 MYPOPI Medical Advisory Panel

04 Intro - Who We Are

05 Our Mission



06 MYPOPI's 2024 Events

07 MYPOPI's 2024 Achievements

08 MYPOPI's 2024 Sponsorship

09 MYPOPI 2024 Activity Plan

10 Our Deepest Gratitude Stakeholder Collaboration



PRESIDENT'S MESSAGE



Bruce W D Lim
PRESIDENT

Dear Members, Partners, and Friends of MYPOPI,

As we reflect on the year 2024, I am filled with pride and gratitude for what we have accomplished together in our mission to champion the lives of those living with Primary Immunodeficiencies (PID) in Malaysia.

This year has been marked by unwavering commitment, growth, and meaningful impact. We expanded our advocacy efforts to new frontiers, raising national awareness on PID through collaborative campaigns, educational forums, and grassroots outreach. A highlight of the year was the launch of MYPOPI–Arcadia: SHINE, our initiative to promote the Expanded Newborn Screening Program. This program represents a vital step toward early detection and timely treatment of PID focusing on SCID and XLA, giving affected newborns a brighter start and families hope and stronger foundation.

We also intensified engagement with policymakers to push for more equitable access to immunoglobulin therapies, including subcutaneous options, and continued our dialogue toward the inclusion of PID treatments in the National Healthcare Blue Book.

Another proud milestone in 2024 was celebrating MYPOPI's 10th Anniversary, marked by our heartfelt Charity Gala Dinner: "Feast with a Heart". This event was a meaningful tribute to our journey, honouring the resilience of our PID community and uniting supporters who share our vision of a future where no one is left behind.

Our partnerships with international allies, industry sponsors, and local stakeholders have been instrumental in amplifying our voice. From patient education to caregiver support, we stayed true to our core values—empowering families, advocating for lifelong care, and creating platforms where patients are seen, heard, and supported.

None of these achievements would have been possible without the dedication of our MYPOPI team, medical advisors, volunteers, and every family that bravely shares their journey. To our donors and supporters, your generosity sustains our vision and lights the way forward.

As we look ahead, we carry with us the momentum of 2024, committed to building a future where no one with PID is left behind. Together, we are not just making a difference—we are shaping lasting change.

With gratitude and hope,

Bruce W D Lim
President
Persatuan Pesakit Imunodefisiensi Primer Malaysia (MYPOPI)

EXECUTIVE COMMITTEE AND BOARD MEMBERS

EXECUTIVE COMMITTEE

Bruce Lim - President and Co-Founder

Siti Aminah Binti Amir - Vice President

Karen Koh - Secretary and Co-Founder

Syamsyiah Binti Hyder Ali - Assistant Secretary

Saravanan Valiatham - Treasurer

BOARD MEMBERS

Arif Fadzilah

Soh An Hok

Ir. Zulkefli Mohd Ghazali - Co Founder

Latifah Binti Abdul Majid

Nur Hidayah Binti Bakhtar

MEDICAL ADVISORY PANEL

2024

MEDICAL ADVISORY PANEL

Dr. Amir Hamzah Abdul Latiff
Chairman Medical Advisory Panel
Allergy & Immunology Centre
Pantai Hospital Kuala Lumpur

Dr. Intan Juliana Abd Hamid
Vice Chairman Medical Advisory Panel
Primary Immunodeficiency Diseases Research Group
Department of Clinical Medicine
Institut Perubatan & Pergigian Termaju, USM

Prof. Dr. Lokman Mohd Noh
Honorary Medical Advisor
(Immunology)

Assoc. Prof. Dr. Intan Hakimah
Medical Advisor
Consultant Paediatrician and Clinical Immunologist & Allergist
Head Clinical Immunology Unit
Department of Paediatrics Faculty of Medicine and Health Sciences
Universiti Putra Malaysia

Assoc. Prof. Dr. Adli Ali
Medical Advisor
Consultant Pediatric Immunologist and Senior Lecturer
Department of Pediatrics
Faculty of Medicine UKM
Hospital Pakar Kanak- Kanak, UKM

Dr. Kent Woo
Medical Advisor
Consultant Physician, clinical immunologist and allergist
Allergy Immunology
Clinic Gleneagles Hospital Kuala Lumpur

MEDICAL ADVISORY PANEL

2024

MEDICAL ADVISORY PANEL

Dr. Adiratna Mat Ripen

Medical Advisor

Immunologist and Head of Cancer Research Centre (CaRC)

Institute for Medical Research (IMR)

National Institutes of Health (NIH)

Ministry of Health Malaysia

Dr. Mohd Azri bin Zainal Abidin

Medical Advisor

Paediatric Clinical Immunologist and Allergist

Department of Paediatrics

Hospital Sultan Abdul Aziz Shah, UPM

Dr. Sangeetha Siniah

Medical Advisor

Paediatric Infectious Disease and Immunologist

Department of Paediatrics

Hospital Tunku Azizah, Hospital Wanita dan Kanak-kanak Kuala Lumpur

Dr Marina Md Sham

Medical Advisor

Paediatric Infectious Disease and Immunologist

Department of Paediatrics

Hospital Tunku Azizah, Kuala Lumpur

Assoc. Prof. Dr. Asrul Bin Abdul Wahab

Medical Advisor

University Lecturer

Jabatan Mikrobiologi & Imunologi Perubatan

Dr. Zarina Thasneem Zainudeen

Medical Advisor

University Lecturer

Department of Clinical Medicine

Institut Perubatan dan Pergigian Termaju, USM

Dr. Ilie Fadzilah Binti Hashim

Medical Advisor

Lecturer

Department of Clinical Medicine

Institut Perubatan dan Pergigian Termaju, USM



ABOUT MYPOPI



Persatuan Pesakit Immunodefisiensi Primer Malaysia (MYPOPI) is a nonprofit organisation and registered society caring for patients and supporting families affected by Primary Immunodeficiencies (PID).

Our aims are to help ensure that those affected by a primary immunodeficiency have the knowledge needed to manage their condition effectively and to ensure that their health needs are understood and addressed by those involved in policy and delivery of healthcare

OUR MISSION



To provide various forms of support to individuals or families affected by PID in Malaysia.



Become a reference center for Malaysians who need information in all aspects related to PID



Spread awareness and understanding about PID in Malaysia.



Be a representative and intermediary for PID patients in Malaysia in fighting for their rights and needs.



Collaborate with stakeholders in conducting studies and research in all aspects related to PID



[HTTPS://WWW.MYPOPI.ORG/](https://www.mypopi.org/)

2024 HIGHLIGHTS

- **SPONSORSHIP**
- **ACHIEVEMENTS**
- **EVENTS**





2024

MYPOPI SPONSORSHIP

We in this together



I P O P I : M Y P O P I S H I N E – E X P A N D E D N E W B O R N S C R E E N I N G A D V O C A C Y (P H A S E I I)

Following the success of IPOPI NBS Advocacy project started in Malaysia as a pilot seed to spearhead SCID NBS in region of SEA in 2023-2024, we extend our heartfelt thanks to IPOPI generously extending their sponsorship to MYPOPI for Phase 2 of the SHINE Program: Expanded Newborn Screening focusing on Treatable Rare Diseases.

Phase 2 of the project will consist of a follow through workshop with relevant stakeholders from the ministry of health and ministry of education including the PAGs from SMAM, MRDS etc.

The duration of the project is from June 2024 – End of 2025.

The grant also supports targeted screening initiatives for newborns with a known family history of Severe Combined Immunodeficiency (SCID), X-linked Agammaglobulinemia (XLA), and Spinal Muscular Atrophy (SMA), enabling early identification and timely intervention for these high-risk infants.



SUPPORT TO ACCESS TO SCIG TREATMENT

Immunoglobulin (IgG) replacement therapy (IRT) is most crucial and life-long treatment for most PID patients. It is considered “Essential Medicine” for the PID by WHO because its efficiency has been proven and there is no alternative treatment available.

MYPOPI has been advocating for SCIG Treatment as alternative treatment to IVIG especially for patient with difficulty to intravenous access and with the aim of home therapy to improve the quality of life of PID patients. Hoping that one day this treatment will be inserted into KKM blue book as indication of treatment for PID and CIDP patients nationwide.

MYPOPI sincerely hopes that in 2024, CSL Behring will continue its support by providing access to SCIG treatment for the five PID patients, ensuring they can maintain their health and quality of life.

Thank you CSL Behring for your continuous support for access to SCIG treatment for patients in Malaysia.





2024

MYPOPI ACHIEVEMENTS

Let's recap the achievements



MYPOPI X DR. AMIR HAMZAH: NEW JOURNAL PUBLICATION

09 January 2024

Inborn errors of immunity (IEI), also known as primary immunodeficiencies (PID); are currently growing group of over 450 different disorders that are characterized by defects in some of the components of the immune system.

The severity of this condition varies, but without adequate treatment and care, anyone suffering from IEI will face a lifetime of compromised health, which could result in lifelong functional disabilities, physical incapacitation, and even death.

Asia Pacific Allergy

OPEN

Hypothesis & Experience

Accessibility to plasma-derived medicinal products in Malaysia: The challenges faced by patients with inborn errors of immunity

Bruce Wee Diong Lim^{1,2}, and Amir Hamzah Abdul Latiff^{3,4,*}

ABSTRACT

Inborn errors of immunity (IEI) (also known as primary immunodeficiencies) is an umbrella term for a growing group of over 450 different disorders that are characterized by defects in some of the components of the immune system. IEI are chronic diseases of genetic origin that render individuals suffering from them susceptible to infections. The mainstay of treatments for most patients with IEI, that is, predominantly antibody deficiencies is immunoglobulin replacement therapy (IRT), which is commonly delivered intravenously. Immunoglobulin (IG) therapy contains antibodies to compensate for the defective immune system's inability to produce them. Individuals with IEI need IRT regularly throughout their lives to help combat infections and prevent organ damage. Without IRT, they are in danger of suffering from morbidity, poor quality of life, and reduced life expectancy. In the last 20 years, the use of IG preparation has tripled and this is partly attributed to the growing awareness and improved diagnoses of IEI cases. IG preparations are also used for the treatment of other medical conditions including secondary immunodeficiencies and autoimmune diseases. As IG is derived from human plasma, there are concerns about the availability of supply, particularly to treat life-threatening conditions that cannot be improved with other medications. It is estimated that 75% to 80% of IEI patients do not have access to adequate IG therapy throughout the world. This concern of supply and other challenges faced by patients with IEI in Malaysia are described from the patients' perspective.

Keywords: Immunoglobulin; immunoglobulin replacement therapy; inborn errors of immunity; Malaysia; plasma-derived plasma products; primary immunodeficiencies

Inborn errors of immunity (IEI) (also known as primary immunodeficiencies) is an umbrella term for a growing group of over 450 different disorders that are characterized by defects in some of the components of the immune system. IEI are chronic diseases of genetic origin that render individuals suffering from them susceptible to infections. IEI vary in severity but without proper treatment and care, every individual suffering from IEI will face a lifetime of compromised health, which could lead to permanent functional impairments, physical incapacitation, and even death. This will have a profound impact on their quality of life, hampering their ability to function normally and pursue education, career, and social lives.

IEI affect at least 10 million people worldwide where its prevalence is estimated at approximately 1 in 8,000 to 10,000 people [1]. While each of the 450 disorders categorized as IEI may be rare, collectively they occur more commonly than childhood leukemia and lymphoma combined. Despite their higher rate of prevalence than other genetic disorders such as hemophilia (less than 15,000), cystic fibrosis (30,000), and Huntington disease (30,000) [2], IEI has a much lower profile and are less known to the general public [3]. Hence, the status of IEI as a rare disease is increasingly being called into question as new knowledge and understanding about it continue to emerge.

The mainstay of treatments for most patients with IEI, that is, predominantly antibody deficiencies is immunoglobulin replacement therapy (IRT), which is commonly delivered intravenously (IGIV). Immunoglobulin (IG) therapy contains antibodies to compensate for the defective immune system's inability to produce them. Individuals with IEI need IRT regularly throughout their lives to help combat infections and prevent organ damage. Without IRT, they are in danger of suffering from morbidity, poor quality of life, and reduced life expectancy.

In the last 20 years, the use of IG preparation has tripled and this is partly attributed to the growing awareness and improved diagnoses of IEI cases. IG preparations are also used for the treatment of other medical conditions including secondary immunodeficiencies and autoimmune diseases. As IG is derived from human plasma, there are concerns about the availability of supply, particularly to treat life-threatening conditions that cannot be improved with other medications. It is estimated that 75% to 80% of IEI patients do not have access to adequate IG therapy throughout the world [4].

*Correspondence to: Amir Hamzah Abdul Latiff, Allergy & Immunology Centre, Pantai Hospital Kuala Lumpur, 6 Jalan Bukit Pantai, 59100 Kuala Lumpur, Malaysia
Tel: +60123050022
Email: amirlatiff@pau.edu.my
Copyright © 2024, Asia Pacific Association of Allergy, Asthma and Clinical Immunology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Received: 3 May 2023; Accepted: 9 January 2024
Published online xxx xxx 2024
<http://dx.doi.org/10.5415/apallergy.0000000000000136>

Discover the challenges faced by patients with inborn errors of immunity in Malaysia

Read more on our website:

[Journal Publication](#)

12 January, 2024

MYPOPI – UKM COLLAB RESEARCH PAPER

MYPOPI is proud to collaborate with University Kebangsaan Malaysia on this research paper – **“Knowledge, Awareness, and Perception on Genetic Testing for Primary Immunodeficiency Disease Among Parents in Malaysia: A Qualitative Study”**.

This study spanned from May 2023 to July 2023 included participants from diverse regions of Malaysia who had undergone different diagnostic journeys in various hospitals.

This study aimed to determine the level of awareness and understanding of genetic testing, the journey towards diagnosis and treatment, emotional impact and psychological factors, and the importance of medical experts in diagnosing and managing PID, as well as public perception and awareness.

This study highlights the diverse knowledge, awareness, and perception surrounding genetic testing for PID.

This research paper was published in Frontiers in Immunology on 12 January 2024.

To access the publication click on the link below: [UKM Research Paper](#)

DR. LOKMAN ON IMMUNOGLOBULIN ACCESS FOR PAD PATIENTS AT 2024 SHINE WORKSHOP

23 January 2024

Ever wondered why access to Immunoglobulin Therapy (IRT) is so crucial for patients with Primary Antibody Deficiency (PAD)

PAD patients cannot produce their own antibodies and need lifelong treatment every 3–4 weeks to survive—just like how insulin is essential for diabetics. However, limited supply and high costs make access difficult, especially in university hospitals.

Dr. Lokman Mohd Noh highlights that full subsidies and proper specialist care are needed to ensure PAD patients get the life-saving treatment they deserve.

[Read the article here](#) by CodeBlue below to learn more!

HELP RAISE MONEY FOR BONE MARROW TRANSPLANT

JAASRITHA SAI



1 MYPOPI are tasked to help family of baby Jaasritha Sai to raise RM300K for bone marrow transplant to be performed in Chennai, India.

++
++
++
++

2 Baby Jaasritha has been diagnosed with a rare severe combined primary immunodeficiency disease called SCID. Without a life-saving bone marrow transplant (BMT), she will not survive — it is a mission against time to save her life

3 MYPOPI extends our heartfelt gratitude to all generous donors who made it possible in such a short period of time, giving Baby Jaasritha a precious chance to live.

AMSA ALUMNI CLUB REUNION ASIA HEALTH FORUM & AMSAAC DINNER MALAYSIA 2024



MYPOPI was honoured to be able to grant a small token sponsorship for AMSA Alumni Club Reunion: Asia Health Forum & AMSAAC Dinner Malaysia 2024.


The reunion event offers opportunities for alumni to engage in the Asia Health Forum, themed “Unlocking the Extraordinary Potential within Medicine”. This forum will serve as a platform for knowledge exchange, where alumni can share their expertise, insights, and experiences with one another. By fostering a culture of continuous learning and education, aimed to empower our alumni to make meaningful contributions to the field of healthcare and beyond.



2024

MYPOPI EVENTS

Let's recap the events




21 April 2024

WORLD PI WEEK 2024

WPIW WITH KKM

With the launch of first PID Patient booklet “Meniti Perjalanan Kehidupan Bersama Penyakit Immunodefisiensi” in Malaysia in 2023. MYPOPI with the collaboration with Kementerian Kesihatan Malaysia (KKM), Agenda Nasional Malaysia Sihat, and MyHEALTH, published this booklet as national PID awareness campaign.



Additionally, MYPOPI will share materials with the Malaysian Ministry of Health (KKM) for posting on their official social media channels. This collaboration aims to reach a broader audience, ensuring vital PID information is accessible to all.

This booklet is not only a helpful guide for patients and their families, but also Malaysians at large in our efforts to increase greater awareness of PID among the public and medical



[Read the booklet here](#)

24 -26 April 2024

Collaboration with IPPT USM Bertam, Penang

WORLD PI WEEK 2024

PUBLIC AWARENESS PROGRAM


MYPOPI has been dedicated to raising awareness about Primary Immunodeficiency Disorders (PID) by hosting the World Primary Immunodeficiency Week (WPIW) annually. This April this year, MYPOPI collaborated with IPPT USM Bertam, Penang targeted the Northern region of West Malaysia; aims to educate the public about PID, fostering understanding and support for families and patients affected with PIDs.

Posters of patients or/and parents' stories are displayed for public reading. Leaflets with 10 warning signs are explained and distributed to public.

More importantly, MYPOPI able to connect with families from the Northern region and recruitment to MYPOPI family membership.



MYPOPI COLLABORATED WITH THE MINISTRY OF HEALTH MALAYSIA



11 June 2024

On 11 June 2024, MYPOPI collaborated with the MINISTRY OF HEALTH MALAYSIA to publish the MyHealth for Life e-Magazine, June 2024 Edition. The magazine was officially released on the official Info Sihat website and the MyHealth portal.


In this edition, MYPOPI and MRDS were given the opportunity to share about rare diseases in general, as well as an interview with a Malaysian rare disease family.

Flip to pages 38 to 41 to read the inspiring story of Siti Aminah's family, titled "Facing Life's Challenges with Iskandar, a Hyper IGM Syndrome Patient."

Learn more in the MyHealth for Life e-Magazine, June 2024 Edition at: <https://bit.ly/4evlTkj>

NATIONAL NURSING SYMPOSIUM ON CLINICAL IMMUNOLOGY 2024

12 - 13 JUNE 2024



MAIN AUDITORIUM HOSPITAL SULTAN ABDUL AZIZ SHAH (HSAAS) UPM



At the 12th National Clinical Immunology Symposium & Practical Paediatrics Update 2023 seminar hosted by UPM Hospital from May 11th to 13th, MYPOPI, a prominent advocate for Primary Immunodeficiency (PID) awareness, played a pivotal role. Amidst the symposium's bustling atmosphere of knowledge exchange, MYPOPI delivered a captivating presentation focusing on patient and family engagement in PID care.

With expertise, MYPOPI sheds light on the challenges faced by PID patients and their families, offering valuable insights to enhance care quality. But MYPOPI's impact didn't stop there. They also set up an interactive exhibition booth, brimming with educational resources and engaging displays. Attendees and the public alike were invited to explore the nuances of PID, fostering greater awareness in the community.

Throughout the symposium, MYPOPI's passionate advocacy left a lasting impression on all attendees. Their proactive engagement showcased the importance of raising awareness and support for PID, inspiring others to join the cause.

LAUNCH OF SHINE PROGRAM

28
JUNE
2024





MYPOPI is proud to announce the launching of the SHINE program, in collaboration with Arcadia Life Sciences Sdn Bhd (ARCADIA) and Revvity Singapore Pte Ltd (REVVITY).

SHINE (which stands for Screening for Health, Intervention, and Nurturing of Every Child) Program aims to avail newborn babies in Malaysia and Southeast Asian (SEA) regions access to expanded Newborn Screening (ENBS) which includes the comprehensive testing of newborns for a wide range of genetic, metabolic, and congenital disorders.



SHINE program would be a game changer to allow access to timely diagnosis and appropriate treatment for children suffering from serious and life-threatening disorders.

This landmark collaboration hopes to ensure that all babies can have equitable access to newborn screening; a life-saving tool for conditions such as Severe Combined Immunodeficiency (SCID) which is in line with Malaysia's national policy on Rare Diseases.



SHINE Program will lead to raising more awareness and coverage for rare and metabolic diseases such as Severe Combined Immunodeficiency (SCID), Spinal Muscular Atrophy (SMA), X-linked agammaglobulinemia (XLA) and Inborn Errors of Metabolism (IEM) in Malaysia and SEA Region. ARCADIA aims to screen 20,000 newborns over the next two years using the ENBS platform. Let us seize this opportunity to collaborate, innovate, and advocate for the effective implementation of this program. Together, we can create a healthier, brighter future for our children and generations to come.

HIZENTRA MANUAL PUSH DEMO WORKSHOP

28 AUGUST 2024

HSAAS UPM, SERDANG, SELANGOR



Thank you, CSL Behring in collaboration with HPUPM Clinical Immunology Dept., for the amazing opportunity to learn alongside expert nurse from New Zealand on Hizentra Manual Push demonstration workshop. This workshop aim to introduce an alternative subcutaneous infusion route immunoglobulin therapy (SGIg) to families or patients currently on SCIg treatment using pump infusion.



MYPOPI EDUCATIONAL DAY 3.0

15 SEPTEMBER 2024
ZECON HOTEL, KUALA LUMPUR



MYPOPI EDUCATIONAL DAY 3.0



On 15th September 2024, the Persatuan Pesakit Imunodefisiensi Primer Malaysia (MYPOPI) successfully hosted the MYPOPI Educational Day 3.0, thanks to the generous financial support from CSL Behring Pte Ltd and Takeda (M) Sdn Bhd. The event featured videography by XPODIUM and volunteer assistance from AMSA.

The primary goal of the Educational Day 3.0 was to deepen understanding of Primary Immunodeficiency (PID) and to raise early awareness of the symptoms that can affect both patients and their families. Additionally, MYPOPI provided an opportunity for PID families and patients to share their experiences of living with PID along with others. These stories aimed to enlighten participants who were attending the Educational Day for the first time.

MYPOPI welcomed 80 participants, including patients, families, members of the MYPOPI Medical Advisory Panel, AMSA representatives, and industry representatives from Takeda (M) Sdn Bhd. Attendees traveled from various regions, including Selangor, Kuala Lumpur, Melaka, Johor, Pahang, Perak, Kelantan, and Kedah.

AMSA AGM: MYPOPI SHARING

9 NOVEMBER 2024 HCTM UKM, KUALA LUMPUR

Dear MyPOPI,

It is that time of the year again for us to gather together to celebrate our tenure, and pass on the duty to the next in line.

On behalf of AMSA Malaysia and the organising committee of the 41st Annual General Meeting, it is my great pleasure to cordially invite you to our most anticipated event of the term – AMSA Malaysia 41st Annual General Meeting (AGM).

The details of the AGM is as follows:

Date: 9th November 2024 (Saturday)

Time: 8.00am - 4.30 pm (GMT +8)

Venue: Auditorium Hospital Canselor Tuanku Muhriz, Clinical Block, Faculty of Medicine UKM

During the AGM, we will be presenting our reviews to our stakeholders. Together with that, is a segment dedicated to our annual report presentations and past news releases to give you a glimpse of what we have achieved as a whole this past year.

There is also a slot allocated for MYPOPI to deliver your presentation during the AGM. During the 5 minutes, I would like to cordially invite you to have a short speech regarding MyPOPI to our audience. You may opt to present in person during the meeting or send us a video presentation of a maximum of **5 minutes**. The scope of topics to be presented, along with more information with regards to the AGM can be found in the "Terms of Reference" attached.

To RSVP, I kindly request you to reply to this email by the **1st of November 2024**. Please do inform us as well if you will be submitting a video presentation or if you will be presenting in person during the day.

Should you have any further enquiries, feel free to write back to me or contact me (**60195528168**).

Thank you and we hope to see you there!

It is our pleasure to be your hand-in-hand partner this tenure, and we hope to strive for even greater heights together next year.

MYPOPI is honoured and grateful to be AMSA lifetime partner. Hence, Mr Bruce Lim, President of MYPOPI was invited to AMSA AGM to share reflection on collaborations and successful events held by MYPOPI-AMSA partnership in year 2023 & 2024.



10th Anniversary CHARITY GALA DINNER

Feast with **Heart:**




Together We Can Make A Difference For
Primary Immunodeficiencies



MYPOPI CHARITY GALA DINNER

Courtyard by Marriott KL South (Puchong)

30 November 2024



Event Highlight

An unforgettable evening dedicated to making a difference.

Hall fully filled with honorable guests are a powerful testament to your commitment to improving the lives of individuals and families navigating this condition.

We celebrate not just our shared mission but also the incredible strength and resilience of those living with Primary Immunodeficiency. Through your generosity, we can provide vital resources, raise awareness, and foster a supportive community for those in need.

Feast with **Heart** – Enjoy the inspiring stories, exquisite dining, and the camaraderie of fellow supporters. Together, we are making a meaningful impact.

Thank you for being an essential part of this journey.






2024

MYPOPI FINANCIAL REPORT

Your donation to our charity
is much appreciated





FINANCIAL OVERVIEW



This report outlines MYPOPI's financial performance for the year ending 31 December 2024. It includes a summary of income and expenses, year-end fund balance, and a comparison with the previous year.

	2023	2024
Income Total	MYR 1,205	MYR 14,732.58
Expenses Total	MYR 12,590.03	MYR 6,211.53
Surplus / Deficit (-) for the year	(MYR 11,385.03)	MYR 8,521.05
Total funds brought forward at 1 st Jan	MYR 13,724.92	MYR 2,339.89
Total fund carried forward as at 31 st DEC	MYR 2,339.89	MYR 10,860.94


In 2024, MYPOPI recorded a total income of MYR 14,732.58, a significant increase compared to MYR 1,205.00 in 2023. Total expenses in 2024 were MYR 6,211.53, resulting in a surplus of MYR 8,521.05. This is a positive turnaround from the deficit of MYR 11,385.03 in 2023.

The fund balance carried forward as of 31 December 2024 stood at MYR 10,860.94, up from MYR 2,339.89 at the end of the previous year. This improvement reflects better income generation and more efficient spending during the year.

TABUNG KEBAJIKAN

Diagnostic Grant
RM 4,250.00

Travel Expenses
RM 1,462.00



MYPOPI established the Tabung Kebajikan Pesakit (Patient Welfare Fund) in 2015 to provide financial aid for diagnostic tests, medical equipment, travel expenses, and essential supplies, with the aim of supporting patients in need.

According to the data above, the majority of expenses in 2024 were allocated to diagnostic grants, accounting for 68.4% of the total financial aid provided to patients.

Despite this positive progress, it remains crucial to continue strategic fundraising efforts to ensure the long-term sustainability of the fund and to support an increasing number of patients in the future.

YOUR DONATION BRINGS HOPE TO PID PATIENTS IN MALAYSIA

Your contribution to Tabung Kebajikan Pesakit is more than just a donation — it is hope, dignity, and relief for patients in need. Every ringgit you give helps ease the burden of those battling illness, ensuring they receive the care, treatment, and support they deserve. Together, we can lift lives, heal hearts, and create a greater impact for a healthier tomorrow. Be the reason someone finds strength in their hardest moment — donate today and be part of this greater cause.



Acc No: 5148 9706 4622

Persatuan Pesakit PID

Reference:

#TabungKebajikanPesakit

Dermaan Tunai kepada MYPOPI adalah ditakluk kepada "Potongan Di Bawah
Subseksyen 44(6), Akta Cukai Pendapatan 1967, No. Rujukan:
LHDN.01/35/42/51/179-6.8744

Tempoh Kuatkuasa Kelulusan: 01 Januari 2023 Sehingga 31Disember 2027"

OUR DEEPEST GRATITUDE TO:

CSL Behring
Biotherapies for Life™



Arcadia
Life Sciences



We sincerely thank you for your invaluable support, which has played a key role in our achievement.



Persatuan Pesakit Immunodefisiensi Primer Malaysia

MYPOPI is a non-profit charity registered in Malaysia (ROS Reg. No: PPM-008-14-15082014), MYPOPI also is a member of IPOPI, an international non-profit association registered in UK.

email: mypopi@yahoo.com - website: mypopi.org